IS6555A - Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni - Google Patents

Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni

Info

Publication number
IS6555A
IS6555A IS6555A IS6555A IS6555A IS 6555 A IS6555 A IS 6555A IS 6555 A IS6555 A IS 6555A IS 6555 A IS6555 A IS 6555A IS 6555 A IS6555 A IS 6555A
Authority
IS
Iceland
Prior art keywords
treatment
vascular damaging
separate doses
vasodilatory activity
damaging agent
Prior art date
Application number
IS6555A
Other languages
English (en)
Inventor
David Davis Peter
Original Assignee
Angiogene Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013928A external-priority patent/GB0013928D0/en
Priority claimed from GB0014904A external-priority patent/GB0014904D0/en
Application filed by Angiogene Pharmaceuticals Ltd. filed Critical Angiogene Pharmaceuticals Ltd.
Publication of IS6555A publication Critical patent/IS6555A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IS6555A 2000-03-31 2002-09-19 Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni IS6555A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013928A GB0013928D0 (en) 2000-06-08 2000-06-08 Methods of treatment
GB0014904A GB0014904D0 (en) 2000-06-20 2000-06-20 Methods of treatment
PCT/GB2001/001329 WO2001074369A1 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Publications (1)

Publication Number Publication Date
IS6555A true IS6555A (is) 2002-10-18

Family

ID=27255635

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6555A IS6555A (is) 2000-03-31 2002-09-19 Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni

Country Status (23)

Country Link
US (1) US20030055024A1 (is)
EP (1) EP1272200B1 (is)
JP (1) JP2003528921A (is)
KR (1) KR20020084267A (is)
CN (1) CN1422157A (is)
AT (1) ATE298240T1 (is)
AU (2) AU4258601A (is)
BR (1) BR0109671A (is)
CA (1) CA2402078A1 (is)
CZ (1) CZ20023231A3 (is)
DE (1) DE60111622T2 (is)
EE (1) EE200200549A (is)
ES (1) ES2243466T3 (is)
HU (1) HUP0300576A3 (is)
IL (1) IL151627A0 (is)
IS (1) IS6555A (is)
MX (1) MXPA02009603A (is)
NO (1) NO20024683L (is)
NZ (1) NZ534190A (is)
PL (1) PL357282A1 (is)
PT (1) PT1272200E (is)
SK (1) SK13902002A3 (is)
WO (1) WO2001074369A1 (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
BRPI0411567A (pt) * 2003-06-18 2006-08-01 Angiogene Pharm Ltd uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO86439B (ro) * 1982-01-15 1985-03-31 Eli Lilly And Company Procedeu pentru prepararea unor derivati de acid ascorbic
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
WO1991006668A1 (en) * 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
WO1991015495A1 (en) * 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
CA2108889A1 (en) * 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH11228594A (ja) * 1998-02-16 1999-08-24 Meiji Milk Prod Co Ltd 新規プロゲステロン化合物
EP1189611B1 (en) * 1999-06-14 2006-05-03 Cancer Research Technology Limited Cancer therapy
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent

Also Published As

Publication number Publication date
ATE298240T1 (de) 2005-07-15
EP1272200B1 (en) 2005-06-22
NZ534190A (en) 2007-05-31
PL357282A1 (en) 2004-07-26
HUP0300576A2 (hu) 2003-07-28
KR20020084267A (ko) 2002-11-04
CN1422157A (zh) 2003-06-04
DE60111622T2 (de) 2006-05-18
SK13902002A3 (sk) 2003-05-02
AU2001242586B2 (en) 2004-12-16
NO20024683L (no) 2002-10-15
AU4258601A (en) 2001-10-15
US20030055024A1 (en) 2003-03-20
HUP0300576A3 (en) 2005-02-28
WO2001074369A1 (en) 2001-10-11
IL151627A0 (en) 2003-04-10
EP1272200A1 (en) 2003-01-08
CA2402078A1 (en) 2001-10-11
MXPA02009603A (es) 2004-05-14
NO20024683D0 (no) 2002-09-30
PT1272200E (pt) 2005-09-30
BR0109671A (pt) 2003-02-04
JP2003528921A (ja) 2003-09-30
ES2243466T3 (es) 2005-12-01
CZ20023231A3 (cs) 2003-01-15
EE200200549A (et) 2004-02-16
DE60111622D1 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
IL189546A0 (en) Therapy for the treatment of disease
BG108443A (en) Substituted oxazoliidinones for combinational therapy
AU4258101A (en) Combination therapies with vascular damaging activity
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
DE60138572D1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
SE0102440D0 (sv) New compound
MXPA06001286A (es) Metodos para tratar la inflamacion y enfermedades asociadas con la inflamacion con una estatina y un eter.
PT1272200E (pt) Terapeuticas em doses fraccionadas com actividade de degradacao vascular
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria
TW202619727A (zh) 使用ｊａｋ抑制劑治療化膿性汗腺炎
PL1838392T3 (pl) Leki zawierające selen na śródbłonkowe choroby układu naczyniowego
ATE442848T1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen